Premium
Chromosomal microarray use among women undergoing invasive prenatal diagnosis
Author(s) -
Naqvi Mariam,
Goldfarb Ilona T.,
Hanmer Kaitlin J.,
Bryant Allison
Publication year - 2016
Publication title -
prenatal diagnosis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.956
H-Index - 97
eISSN - 1097-0223
pISSN - 0197-3851
DOI - 10.1002/pd.4835
Subject(s) - chorionic villus sampling , amniocentesis , medicine , obstetrics , prenatal diagnosis , retrospective cohort study , gynecology , pregnancy , fetus , biology , genetics
Objective To study the offer and uptake of chromosomal microarray analysis (CMA) among women undergoing invasive prenatal testing. Methods This is a retrospective cohort study of women who underwent chorionic villus sampling (CVS) or amniocentesis. Charts were reviewed for CMA offer and uptake, in additional to clinical and demographic variables. Results One hundred forty‐one women underwent CVS ( n = 53) or amniocentesis ( n = 91) over the study period. Overall, 41% of women underwent CMA. Women who underwent invasive testing for a fetal structural abnormality were more likely to undergo CMA than women who underwent invasive testing for all other indications (aOR 43.18, 95% CI 4.64 – 401.58). Chromosomal microarray was offered more often to women who primarily spoke English ( p < 0.001), self‐identified as white ( p = 0.046) and did not receive prenatal care in a community health center ( p = 0.044). Statistically significant differences in CMA uptake by race/ethnicity, language, insurance or provider type were not noted. Multiparous women were less likely to accept this test than nulliparas (aOR 0.39, 95% CI 0.17 – 0.86). Conclusion Women who undergo invasive fetal testing are more likely to undergo CMA if the indication is for a fetal structural anomaly. There may be important demographic disparities in the offering of CMA which bear further exploration. © 2016 John Wiley & Sons, Ltd.